ArticleCancers2010
Biomarkers for Basal-like Breast Cancer.
Article in Cancers, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Homologous recombination pathway alterations in basal-like breast cancer.Frontiers in oncology · 2026Review
- Tumor necrosis associates with aggressive breast cancer features, increased hypoxia signaling and reduced patient survival.Scientific reports · 2025Article
- FOXO1 promotes the expression of canonical WNT target genes in examined basal-like breast and glioblastoma multiforme cancer cells.FEBS open bio · 2023Article
- Article
- Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours.Veterinary and comparative oncology · 2020Article
- The Landscape of Targeted Therapies in TNBC.Cancers · 2020Review
- Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.Frontiers in oncology · 2020Article
- The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer.International journal of molecular sciences · 2019Review
- Clinical biomarkers for cancer recognition and prevention: A novel approach with optical measurements.Cancer biomarkers : section A of Disease markers · 2018Review
- Pathway-Based Drug Repositioning for Breast Cancer Molecular Subtypes.Frontiers in pharmacology · 2018Article
- Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis.Breast cancer (Dove Medical Press) · 2018Article
- Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- Analysis of Contractility and Invasion Potential of Two Canine Mammary Tumor Cell Lines.Frontiers in veterinary science · 2017Article
- Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.Oncology letters · 2016Article
- Breed- and age-related differences in canine mammary tumors.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2016Article
- Article
- Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience.SpringerPlus · 2015Article
- MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers.Breast cancer research : BCR · 2014Article
- Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition.PloS one · 2013Article
- Challenges to developing proteomic-based breast cancer diagnostics.Omics : a journal of integrative biology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Initially recognized through microarray-based gene expression profiling, basal-like breast cancer, for which we lack effective targeted therapies, is an aggressive form of carcinoma with a predilection for younger women. With some success, immunohistochemical studies have attempted to reproduce the expression profile classification of breast cancer through identification of subtype-specific biomarkers. This review aims to present an in depth summary and analysis of the current status of basal-like breast cancer biomarker research. While a number of biomarkers show promise for future clinical application, the next logical step is a comprehensive investigation of all biomarkers against a gene expression profile gold standard for breast cancer subtype assignment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.